-
Rotigotine: From Purity to Parkinson’s Assays
2026-09-17
Rotigotine is a dopamine D2/D3 receptor agonist whose broad pharmacology makes experimental design inseparable from chemical and analytical control. This guide connects impurity profiling, stereochemical identity, receptor biology, and Parkinson’s disease research workflows to improve assay interpretation.
-
Phenothiazines, ROS, and Autophagy in Macrophages
2026-09-17
The reference study identifies phenothiazines as host-directed antibacterial lead compounds that strengthen macrophage activity through reactive oxygen species accumulation, lysosomal activation, and autophagy. Perphenazine also reduced tissue lesions and inflammation in a Salmonella Typhimurium infection model, while inhibitor experiments supported ROS and autophagy as functionally important mechanisms.
-
HotStart Universal 2X Green qPCR Master Mix Workflow
2026-09-16
Build more specific, reproducible dye-based assays for neurogenetic studies, including transcriptional rescue experiments inspired by NEXMIF research. This workflow combines hot-start specificity, universal ROX normalization, and melt-curve verification to turn complex cDNA samples into defensible gene expression data.
-
Rotigotine: From Receptor Biology to Translation
2026-09-15
A translational framework for using Rotigotine as more than a symptomatic dopaminergic tool: integrating receptor biology, exposure design, analytical stability, and multimodal Parkinson’s disease research endpoints.
-
Imeglimin and Mitochondrial Function in CTS Cells
2026-09-15
This 2025 study examined whether imeglimin could improve mitochondrial dysfunction in subsynovial connective tissue cells derived from patients with idiopathic carpal tunnel syndrome. Its multi-parameter design linked cellular performance, oxidative stress, mitochondrial structure, gene expression, and permeability-transition biology, providing a useful framework for mechanistic CTS research.
-
Surrogate BBB Model Corrects Lysosomal Trapping
2026-09-14
Hu and colleagues developed a high-throughput Transwell blood-brain barrier surrogate using LLC-PK1-MOCK and LLC-PK1-MDR1 cells, combining permeability, P-glycoprotein efflux, and recovery measurements. The study linked MDR1-derived permeability with unbound brain distribution and showed that bafilomycin A1 correction can improve interpretation of compounds affected by lysosomal trapping.
-
Skin Methylome Aging: Methods and Therapeutic Screening
2026-09-14
Boroni et al. developed a skin-specific DNA methylation age predictor using 508 human skin samples and 2,266 CpG sites. The algorithm captured donor age, cellular passage, skin disease status, and responses to senotherapeutic treatment, creating a molecular endpoint for studying skin aging and evaluating interventions.
-
Twin-Derived iPSCs for Schizophrenia Research
2026-09-13
This reference study generated and characterized two human iPSC lines from dizygotic twins discordant for schizophrenia, creating a paired resource for investigating disease-related genetic and cellular variation. The lines showed pluripotency, genomic stability, three-germ-layer differentiation potential, and identity confirmation, supporting their future use in neural disease modeling and organoid-based research.
-
Disulfiram Workflows for Precision Cancer Research
2026-09-12
Disulfiram supports complementary cancer research workflows, from ALDH2-linked synthetic lethality in APC-deficient colorectal models to copper-associated proteasome inhibition in breast cancer systems. This practical guide connects dosing, orthogonal readouts, model selection, and troubleshooting for more interpretable results.
-
(Z)-4-Hydroxytamoxifen in Relapse Research
2026-09-12
A translational strategy for using (Z)-4-Hydroxytamoxifen to interrogate estrogen receptor biology while interpreting proliferation-tracing models of breast cancer relapse.
-
Perphenazine: From D2 Antagonism to Host Defense
2026-09-11
Perphenazine is more than a conventional dopamine probe. Its phenothiazine receptor binding profile, mitochondrial effects, and emerging host-directed antibacterial activity create a translational framework for connecting neuropharmacology research with immunology while preserving rigorous controls around pleiotropy and cytotoxicity.
-
EZ Cap™ EGFP mRNA Workflow and QC Guide
2026-09-11
EZ Cap™ EGFP mRNA (SKU R1002) provides a Cap 1 EGFP reporter mRNA input for testing delivery and transient expression in research assays. It is appropriate for controlled method development, but the available dossier does not establish a universal dose, cell type, delivery reagent, readout window, or expected result.
-
PP 1: A Mechanistic Map of Src Signaling
2026-09-10
PP 1, a Src family tyrosine kinase inhibitor, can separate kinase-dependent phosphorylation from metabolic vulnerabilities in cancer and immune models. This article explains how to interpret Lck, Fyn, Lyn, RET, and EDI3-related experiments without conflating biochemical potency with disease-specific efficacy.
-
L. reuteri FN041 Reshapes Colitis Microbiota
2026-09-10
This mouse study identifies human milk-derived Limosilactobacillus reuteri FN041 as a potential modulator of DSS-induced colitis through coordinated changes in intestinal inflammation, barrier integrity, gut microbiota, and metabolites. Its main contribution is a multi-omics view of probiotic activity, while its findings remain preclinical and require validation in controlled mechanistic and clinical studies.
-
CX-4945 (Silmitasertib): A CK2 Assay Playbook
2026-09-09
CX-4945 (Silmitasertib) is a selective CK2 inhibitor for dissecting kinase-dependent signaling, apoptosis, and cell-cycle control. This assay-focused guide connects oncology evidence with the CK2–CIAV host-dependency study while clarifying translational limits.